Biotechnology company Commit Biologics has appointed Thomas Montgomery Andresen as CEO as it aims to take its complement-powered immune engagers into clinic. 

Commit described Andresen as “a serial biotech entrepreneur”, with over 20 years of experience building high-value biotech ventures at the intersection of therapeutic innovation and bioengineering.  

Andresen has worked in converting scientific breakthroughs into marketable technologies and has played a role in securing substantial institutional backing to launch and scale multiple biotechnology companies across Europe and the US. 

“Commit is redefining immunotherapy by activating the complement system – one of the immune system’s most potent, yet untapped weapons,” Andresen commented. 

“Since the turn of the century, the immunotherapy field has produced a series of breakthrough modalities, from checkpoint inhibitors to CAR-Ts and T-cell engagers. Commit is at the forefront of what I firmly believe to be the next breakthrough modality: complement-powered immune engagers.   

“The company’s preclinical data is outstanding, and its non-human primate data, in particular, gives me the strong conviction that these positive results will be replicated in the clinic.” 

Andresen’s appointment comes as Commit advances a pipeline of proprietary therapeutics powered by its Bispecific Complement Engager (BiCE) technology platform.  

In November, the company announced positive proof-of-concept data from a non-human primate (NHP) study, providing critical translational validation of the BiCE platform. Results demonstrated rapid, deep, and sustained targeted B-cell depletion without triggering systemic cytokine release – establishing solid safety and efficacy profiles and proof-of-mechanism. 

The company is set to nominate its first two clinical development candidates (DCs) in 2026, which will address key unmet needs in autoimmune disease and oncology. These DCs lead a broader pipeline targeting strategic clinical entry points, focusing on patients with compromised T-cell function, and indications where the differentiated mechanism of action offers new high-value treatment possibilities.